John Cassidy, CEO, Cambridge Cancer Genomics, AI in Oncology

On this episode, I speak with John Cassidy, CEO of Cambridge Cancer Genomics ( www.ccg.ai ). CCG aims to transform oncology by combining liquid biopsy with genomics and artificial intelligence to predict disease progression and improve treatment. On this episode, you’ll learn about the challenges with chemotherapy that CCG is tackling, the role that liquid biopsy and artificial intelligence play in their solution, and how their approach could forever change the way we treat cancer. This episode is brought to you by BenchSci ( www.benchsci.com ). BenchSci uses artificial intelligence to reduce the time, uncertainty, and cost of scientific experiments. Use it to find research antibodies up to 24x faster than using PubMed or Google Scholar. Just enter a protein of interest and filter by technique, organism, tissue, or 13 other options. BenchSci returns only relevant published figures and products. It’s free for academic researchers. Learn more and sign up at www.benchsci.com .

Om Podcasten

Get knowledge and inspiration to apply artificial intelligence to drug development. Discover startups applying machine learning to biomedical research. Hear how biotech and pharma companies use AI to speed discovery and cut costs. Learn from academic researchers pushing boundaries in applying computation to biology. We interview leaders transforming drug development with data and algorithms. Subscribe now and never miss an episode!